Logo

TaiMed Biologics' Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV

Share this

TaiMed Biologics' Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV

Shots:

  • The approval is based on clinical study results assessing Trogarzo (ibalizumab- IV) in 40 patients with MDR-HIV
  • The study resulted in depletion of HIV-RNA level in blood in 43% patients after 24 weeks when given with other antiretroviral drugs
  • Trogarvo (ibalizumab- IV) is an antiretroviral drug used in treatment of MDR-HIV and received FDA’s FT- PR- OD and breakthrough therapy in 2003- 2017- 2014 & 2015 respectively.

Ref: FDA | Image: Bioworld

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions